302 related articles for article (PubMed ID: 19238018)
1. Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials.
Zaritskaya L; Shafer-Weaver KA; Gregory MK; Strobl SL; Baseler M; Malyguine A
J Immunother; 2009; 32(2):186-94. PubMed ID: 19238018
[TBL] [Abstract][Full Text] [Related]
2. Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.
Shafer-Weaver K; Rosenberg S; Strobl S; Gregory Alvord W; Baseler M; Malyguine A
J Immunother; 2006; 29(3):328-35. PubMed ID: 16699376
[TBL] [Abstract][Full Text] [Related]
3. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
4. Evaluating antigen-specific cytotoxic T lymphocyte responses by a novel mouse granzyme B ELISPOT assay.
Ewen CL; Rong J; Kokaji AI; Bleackley RC; Kane KP
J Immunol Methods; 2006 Jan; 308(1-2):156-66. PubMed ID: 16375915
[TBL] [Abstract][Full Text] [Related]
5. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells.
He L; Hakimi J; Salha D; Miron I; Dunn P; Radvanyi L
J Immunol Methods; 2005 Sep; 304(1-2):43-59. PubMed ID: 16076473
[TBL] [Abstract][Full Text] [Related]
6. A flow cytometry-based assay to assess minute frequencies of CD8+ T cells by their cytolytic function.
Stanke J; Hoffmann C; Erben U; von Keyserling H; Stevanovic S; Cichon G; Schneider A; Kaufmann AM
J Immunol Methods; 2010 Aug; 360(1-2):56-65. PubMed ID: 20558172
[TBL] [Abstract][Full Text] [Related]
7. A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry.
Godoy-Ramirez K; Mäkitalo B; Thorstensson R; Sandström E; Biberfeld G; Gaines H
Cytometry A; 2005 Dec; 68(2):71-80. PubMed ID: 16228974
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays.
Langhans B; Ahrendt M; Nattermann J; Sauerbruch T; Spengler U
J Immunol Methods; 2005 Nov; 306(1-2):161-8. PubMed ID: 16202423
[TBL] [Abstract][Full Text] [Related]
9. A novel four-colour flow cytometric assay to determine natural killer cell or T-cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20% of normal cells.
Zimmermann SY; Esser R; Rohrbach E; Klingebiel T; Koehl U
J Immunol Methods; 2005 Jan; 296(1-2):63-76. PubMed ID: 15680151
[TBL] [Abstract][Full Text] [Related]
10. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
11. A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells.
Klöss S; Bochennek K; Huenecke S; Zimmermann SY; Kuçi S; Müller T; Wels WS; Klingebiel T; Esser R; Koehl U
J Immunol Methods; 2007 Aug; 325(1-2):140-7. PubMed ID: 17663991
[TBL] [Abstract][Full Text] [Related]
12. A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood.
Markovic SN; Nevala WK; Uhl CB; Celis E; McKean DJ
Clin Exp Immunol; 2006 Sep; 145(3):438-47. PubMed ID: 16907911
[TBL] [Abstract][Full Text] [Related]
13. LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry.
Devêvre E; Romero P; Mahnke YD
J Immunol Methods; 2006 Apr; 311(1-2):31-46. PubMed ID: 16527300
[TBL] [Abstract][Full Text] [Related]
14. New approaches for monitoring CTL activity in clinical trials.
Malyguine A; Strobl S; Zaritskaya L; Baseler M; Shafer-Weaver K
Adv Exp Med Biol; 2007; 601():273-84. PubMed ID: 17713015
[TBL] [Abstract][Full Text] [Related]
15. The decreased susceptibility of metastatic melanoma cells to killing involves an alteration of CTL reactivity.
Gassara A; Messai Y; Gaudin C; Abouzahr S; Jalil A; Diarra-Mehrpour M; Faure F; Richon C; Avril MF; Even J; Chouaib S
Int J Oncol; 2006 Jul; 29(1):155-61. PubMed ID: 16773195
[TBL] [Abstract][Full Text] [Related]
16. A novel flow cytometric assay for evaluating cell-mediated cytotoxicity.
Burkett MW; Shafer-Weaver KA; Strobl S; Baseler M; Malyguine A
J Immunother; 2005; 28(4):396-402. PubMed ID: 16000959
[TBL] [Abstract][Full Text] [Related]
17. The NK function elucidated with respect to effector cells, target cells and other immunological in vitro tests.
Kristensen E
Tokai J Exp Clin Med; 1983 Dec; 8(5-6):449-53. PubMed ID: 6681340
[TBL] [Abstract][Full Text] [Related]
18. Variables and specificity of in vitro lymphocyte-mediated cytotoxicity in human melanoma.
Mukherji B; Vassos D; Flowers A; Binder SC; Nathanson L
Cancer Res; 1975 Dec; 35(12):3721-30. PubMed ID: 1192430
[TBL] [Abstract][Full Text] [Related]
19. Methods to monitor immune response and quality control.
Whiteside TL
Dev Biol (Basel); 2004; 116():219-28; discussion 229-36. PubMed ID: 15603195
[TBL] [Abstract][Full Text] [Related]
20. Immune monitoring of T-cell responses in cancer vaccine development.
Keilholz U; Martus P; Scheibenbogen C
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2346s-2352s. PubMed ID: 16609057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
